This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MarketWatch
1. Novo Nordisk partners with Septerna on oral obesity medicines. 2. Potential oral drugs may compete with Novo's injectable therapies. 3. Novo will invest up to $2.2 billion in research and development. 4. Market size for oral drugs is expected to be smaller than injectables. 5. Partnership aims to address diabetes and other cardiometabolic diseases.